{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell
Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 21 January 2026, providing investors with the latest view of the stock’s position.
Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?
As of 20-Jan, Akums Drugs & Pharmaceuticals Ltd witnessed a notable decline in its share price, falling 3.5% to ₹422.00. This drop reflects a continuation of recent underperformance driven by weak financial metrics and subdued investor sentiment despite some positive profit growth.
Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell
Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell
Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Akums Drugs & Pharmaceuticals: Technical Momentum Shifts Amid Mixed Market Signals
Akums Drugs & Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent price movements and technical parameters suggest a transition from a mildly bearish stance to a more sideways trend, highlighting a period of consolidation amid fluctuating investor sentiment.
Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals
Akums Drugs has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. The pharmaceutical company’s recent assessment highlights a complex interplay of valuation appeal, financial pressures, and technical signals, set against a backdrop of subdued sector performance and market capitalisation constraints.
Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals
Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.
How has been the historical performance of Akums Drugs?
Akums Drugs has shown significant recovery and growth, with net sales reaching 4,118.16 crore in March 2025, up from 3,654.82 crore in March 2023, and a profit after tax of 343.78 crore, recovering from a loss the previous year. The company's financial position is stable, with improved cash flow and earnings per share increasing to 22.09.
Akums Drugs Faces Financial Challenges Amid Declining Performance Metrics and Rising Costs
Akums Drugs & Pharmaceuticals has faced a decline in financial performance for the quarter ending September 2025, despite reporting a higher profit after tax for the nine-month period. Key indicators show rising interest expenses and a significant drop in quarterly PAT, raising concerns about operational efficiency and financial sustainability.
Akums Drugs Q2 FY26: Profit Plunges 37% as Margins Compress Under Rising Costs
Akums Drugs & Pharmaceuticals Ltd., one of India's leading pharmaceutical contract development and manufacturing organisations, reported a disappointing second quarter for FY2026, with consolidated net profit declining 37.46% year-on-year to ₹40.78 crores from ₹65.21 crores in Q2 FY25. The quarter-on-quarter performance was equally concerning, with profits falling 35.76% from ₹63.48 crores in Q1 FY26. The sharp contraction in profitability comes despite relatively stable revenue, raising questions about operational efficiency and cost management at the ₹6,635 crore market capitalisation company.
How has been the historical performance of Akums Drugs?
Akums Drugs experienced significant fluctuations in financial performance over the past three years, with a notable recovery in FY 2025, reporting net sales of 4,118.16 crore and a profit after tax of 343.78 crore, up from a loss the previous year. Key improvements included a rise in operating profit to 516.61 crore and a substantial increase in earnings per share to 22.09.
Why is Akums Drugs falling/rising?
As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd's stock price is Rs 439.70, down 3.25%, and has declined 6.63% over the last three days. The stock has underperformed significantly over the past year, with a return of -44.83%, amid disappointing financial results and reduced institutional investor participation.
Why is Akums Drugs falling/rising?
As of 20-Oct, Akums Drugs & Pharmaceuticals Ltd is currently priced at 467.40, reflecting a short-term gain despite a significant year-long decline of -48.58%. The stock's recent uptick contrasts with ongoing financial challenges and poor long-term growth metrics.
Is Akums Drugs technically bullish or bearish?
As of October 10, 2025, Akums Drugs shows a mildly bearish trend due to bearish weekly MACD and KST, despite bullish weekly and monthly RSI readings indicating some underlying strength.
Akums Drugs Faces Technical Trend Challenges Amid Market Evaluation Revision
Akums Drugs & Pharmaceuticals has recently revised its evaluation amid challenging market conditions. The stock, currently priced at 448.55, has experienced a significant decline over the past year. Technical indicators present a mixed outlook, with bearish trends noted, while the company's performance lags behind the Sensex.
Is Akums Drugs technically bullish or bearish?
As of October 10, 2025, the market trend is mildly bearish, indicated by bearish weekly MACD and KST indicators, despite some bullish signals from the RSI, suggesting underlying strength.
Is Akums Drugs technically bullish or bearish?
As of October 10, 2025, the trend is mildly bearish due to bearish signals from the weekly MACD and KST indicators, despite some bullish momentum in the RSI readings.
Is Akums Drugs technically bullish or bearish?
As of October 7, 2025, the technical trend is bearish with moderate strength, driven by bearish MACD, moving averages, and Bollinger Bands, while showing divergence with a bullish monthly RSI and significant underperformance against the Sensex.
Akums Drugs Faces Technical Trend Shifts Amid Market Evaluation Revision
Akums Drugs & Pharmaceuticals has recently revised its evaluation amid challenging market conditions, with its stock priced at 440.60. Over the past year, it has experienced a significant decline, contrasting with the Sensex's modest gain. Technical indicators suggest a bearish sentiment, despite some signs of underlying strength.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
